Please find enclosed Earnings Call Transcript - Q2FY27

AI summary - Q2FY27 revenue INR7,404 Cr, +4% Q-o-Q; EBITDA margin 18.7%, +200 bps Q-o-Q - One India business grew 12% Y-o-Y; branded prescription +15%, chronic therapies strong - North America revenue $172 mn; aiming $1 bn exit run rate FY27 - Pipeline: 3 US launches (2 respiratory, 1 peptide) and 4 biosimilars progressing - FDA inspections: Invagen Long Island cleared with 0 observations; Pithampur has 7 observations - R&D spend 5.7% of revenue this quarter; full year guidance 6-7% - Net cash INR9,823 Cr; debt INR699 Cr - Multiple analyst queries on US ramp-up; management confident on launch timing and market share - EBITDA margin guidance for FY27 maintained at 18.5%-20% - India consumer health growing steadily; trade generics mid-single digit Y-o-Y growth - Biosimilar development includes Pembrolizumab partnership with Qilu; filing planned for launch by 2029 patent expiry